## PATENT COOPERATION TREATY

# **PCT**

REC'D 2 0 APR 2006 WIPO

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		FOR FURTHER ACT	TION	See Form PCT/IPEA/416		
9516-335-228 International application No.		International filing date (a	lay/month/year)	Priority date (day/month/year)		
PCT/US04/28742		03 September 2004 (03.09		05 March 2004 (05.03.2004)		
International Patent Classification (IPC) or national classification and IPC						
IPC: A61K 314-35 USPC: 514/417						
Applicant						
CELEGENE CORPORATION						
Ex	1. This report is the international preliminary examination report, established by this International Preliminar Examining Authority under Article 35 and transmitted to the applicant according to Article 36.					
2. Th	2. This REPORT consists of a total ofsheets, including this cover sheet.					
1		anied by ANNEXES, con				
a.	a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:					
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.					
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
This report contains indications relating to the following items:						
1 7 11	<del></del>	_	whig items.			
		asis of the report				
	Box No. II Pr	riority				
L		on-establishment of opini oplicability	on with regard to nov	velty, inventive step and industrial		
	Box No. IV La	ack of unity of invention				
				regard to novelty, inventive step or as supporting such statement		
	<del></del>	ertain documents cited	•			
	Box No. VII C	ertain defects in the interr	national application			
	Box No. VIII C	ertain observations on the	international applica	tion		
Date of submission of the demand			Date of completion	of this report		
05 October 2005 (05.10.2005)			30 March 2006 (30.03	3,2006)		
Name and mailing address of the IPEA/ US			Authorized office	Dullank		
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents			Tenge	- 10MXCW 1)		
P.O. Box 1450			Sreeni Fadmanabhan			
Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201			Telephone No. 571-2	72-0600		
Form PCT/IPE A/100 (over sheet) (April 2005)						

form PCT/IPEA/409 (cover sheet)(April 2005)

## 4/

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.	
DCT/I ISO <i>A/</i> 287 <i>A</i> 2	

Bo	x No.	. I Basis of the report
1.	With	regard to the language, this report is based on:
	$\boxtimes$	the international application in the language in which it was filed.
		a translation of the international application into <u>English</u> , which is the language of a translation furnished for the purposes of:
		international search (under Rules 12.3 and 23.1(b))
		publication of the international application (under Rule 12.4(a))
		international preliminary examination (under Rules 55.2(a) and/or 55.3(a))
	to the	regard to the elements of the international application, this report is based on (replacement sheets which have been furnished a receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not seed to this report):
	Ä	the international application as originally filed/furnished
	$\boxtimes$	the description:
		pages 1-68 as originally filed/furnished pages* NONE received by this Authority on
		pages* NONE received by this Authority on
		the claims:  pages 69-74 as originally filed/furnished pages* NONE as amended (together with any statement) under Article 19 pages* NONE received by this Authority on pages*
	$\boxtimes$	the drawings:
		pages NONE as originally filed/furnished
		pages* NONE received by this Authority on
	<del>,</del>	pages* NONE received by this Authority on
	Ш	a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3.		The amendments have resulted in the cancellation of:
		the description, pages
		the claims, Nos.
		the drawings, sheets/figs
		the sequence listing (specify):
		any table(s) related to the sequence listing (specify):
4. [		This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
		the description, pages
		the claims, Nos.
		the drawings, sheets/figs
		the sequence listing (specify):
		any table(s) related to the sequence listing (specify):
* If	item	4 applies, some or all of those sheets may be marked "superseded."

Form PCT/IPEA/409 (Box No. I) (April 2005)

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US04/28742

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial
	applicability; citations and explanations supporting such statement

#### 1. Statement Claims 14-17 YES Novelty (N) Claims 1-13 and 18-27 NO Claims <u>14-17</u> Inventive Step (IS) YES \_NO Claims 1-13 and 18-27 Industrial Applicability (IA) Claims 1-27 YES Claims NONE NO

#### 2. Citations and Explanations (Rule 70.7)

Claims 1-12, 24-27 lack novelty under PCT Article 33(2) as being anticipated by Tobinick (US 6, 623,736). Tobinick discloses a method of treating central nervous system disorder such Alzheimer's disease by administering antagonists of cytokines. See column 1, lines 9-20, lines 56-60. A combination therapy is also disclosed. See column 9, lines 5-35. Thus Tobinick anticipates instant claims 1-12, 24-27.

Claims 1-4, 7-8, 13, 18-19, and 24-26 lack novelty under PCT Article 33(2) as being anticipated by Muller (WO 97/08143). Muller discloses a method of treating central nervous system disorder such as multiple sclerosis by administering cytokine inhibitors of the instant invention formula (I). See page 1, line 5, page 3 line 30-page 4, line 7; page 5, lines 15-page 7. Thus Muller anticipates instant claims 1-4, 7-8, 13, 18-19, and 24-26.

Claims 1-8, 20-21, and 24-26 lack novelty under PCT Article 33(2) as being anticipated by Muller (WO 99/06041). Muller discloses a method of treating central nervous system disorder such as multiple sclerosis by administering cytokine inhibitors of the instant invention formula (II). See page 1, line 11; page 5 lines 30-33; page 7, lines 1-25. Thus Muller anticipates instant claims 1-8, 20-21, and 24-26.

Claims 1-4, 7-8, and 22-26 lack novelty under PCT Article 33(2) as being anticipated by Schafer (WO 03/080048). Schafer discloses a method of treating disorders ameliorated by reduction of TNF-alpha by administering cytokine inhibitors of the instant invention formula (III). See page 1, and page 6 Thus Schafer anticipates instant claims 1-4, 7-8, and 22-26.

Claims 1-27 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.

Form PCT/IPEA/409 (Box No. V) (April 2005)